Skip to content

Enbiosis “The World’s First Digital Twin & AI Powered Nutraceutical Formulation Engine”

About Us

The company that turns food into medicine.

Scientific Foundations

In 2004, while pursuing his PhD at the University of Nebraska-Lincoln, Prof. Dr. Özkan Ufuk Nalbantoglu (LinkedIn, opens in a new tab) envisioned something far ahead of its time: analysing the human microbiome using artificial intelligence. At that moment, the technology to even generate such data did not yet exist.

Years later, as next-generation sequencing matured, the algorithms Prof. Nalbantoglu had developed were adopted by the Earth Microbiome Project; the world’s largest microbiome initiative. What began as a theoretical study had evolved into a globally recognised scientific infrastructure.

From 2014 onward, Prof. Nalbantoglu pushed the work further; developing algorithms not only to analyse the microbiome, but to modulate it in ways that could directly improve human health. That body of work, refined across more than fifteen years in bioinformatics and microbiome research, became the scientific foundation on which Enbiosis was built.

Portrait of Enbiosis Chief Technical Officer, in a burgundy shirt against a white background

Assoc. Prof. Özkan Ufuk Nalbantoğlu

Chief Technical Officer (CTO)

Visionary Leadership

Ömer Özkan (LinkedIn, opens in a new tab) is a serial entrepreneur and early-stage investor with an unusual appetite for high-conviction bets in deep-tech and science-led sectors. Over the past decade, he has invested across solar energy, legal technology, education, autonomous systems and healthcare; backing companies that challenge incumbents through technology rather than incrementalism.

The pivotal moment came in 2018, when Özkan met Prof. Nalbantoglu. Struck by the depth of his academic background and the clarity of his long-range vision, Özkan became convinced that the microbiome could redefine how we diagnose and treat disease. Enbiosis was founded in 2019, and from that moment on, Özkan closed every other chapter of his career to dedicate himself to one mission: turning microbiome science into a global health company.

Portrait of Ömer Özkan, Chief Executive Officer, wearing glasses and a dark blazer with arms folded

Ömer Özkan

Chief Executive Officer (CEO)

The Technology

Technology Journey

Enbiosis has evolved in two distinct generations. The first established us as a clinically-validated leader in microbiome-based personalised nutrition. The second is a category-defining leap into Digital Twin & AI-Powered nutraceuticals.

Enbioma: Microbiome Analysis & Personalised Nutrition

Enbioma is an AI-powered SaaS platform that analyses gut microbiome data and generates personalised nutrition strategies for microbiome modulation. It holistically evaluates the relationship between the trillions of bacteria in the gut and the individual’s general health parameters, then designs an optimal diet strategy to drive each microbiome profile toward a healthier state.

The platform runs on microbiome data from tens of thousands of profiles, growing every day. It is delivered as a cloud-based system that allows partners; hospitals, laboratories, diagnostic centres and wellness clinics; to upload sequencing data and automatically generate individualised microbiome reports.

Clinical validation; peer-reviewed and repeatable

Our scientific approach is led by a multidisciplinary team combining computational modeling with clinical expertise. Dr. Ufuk Nalbantoğlu (CTO) leads our digital twin–based modeling, while Varol Tunalı, MD, PhD, oversees clinical strategy and study management, and Beyza Hilal Ermiş, MSc leads clinical nutrition. This structure is supported by experts in bioinformatics, clinical operations, and data science, enabling the translation of microbiome science into clinically actionable solutions. Our work and technology has been validated by multiple peer-reviewed publications and has been presented at leading international congresses.

These are not preprints, not observational white papers, not sponsored retrospective studies. Four of these are clinical studies of the personalised diet approach, including two randomised controlled trials. Together, they make Enbiosis the only company in microbiome-based nutrition whose technology can be considered a clinically proven treatment tool.

  1. The American Journal of Gastroenterology
    The American Journal of Gastroenterology (2024)

    A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome.

  2. Gut Microbes
    Gut Microbes (2026)

    Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial.

  3. Gut Microbes
    Gut Microbes (2022)

    Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome.

  4. Journal of Clinical Medicine
    Journal of Clinical Medicine (2022)

    Efficacy of AI-Assisted Personalized Microbiome Modulation by Diet in Functional Constipation: A Randomized Controlled Trial.

  5. Molecular Nutrition & Food Research
    Molecular Nutrition & Food Research (2024)

    A Shotgun Metagenomics Investigation into Labeling Inaccuracies in Widely Sold Probiotic Supplements in the USA

  6. Biomedical Signal Processing and Control
    Biomedical Signal Processing and Control (2025)

    Deep learning-enhanced wellness scores: a population-level study on gut microbiome profiling and health prediction.

World map showing the countries where Enbiosis has licensed partners

Commercial Footprint

Enbioma has since been deployed by licensed partners in the UK, US, Canada, Latin America, the Middle East and Southeast Asia, with thousands of individual reports delivered. The United Kingdom formally recognised Enbiosis as one of the best technology companies across Europe (including Israel); a rare distinction for a microbiome start-up.

The Nutraceutical Formulation Engine

If Enbioma was the best personalised-nutrition platform in the world, Enbiosis is a different category altogether. It marks our transition from AI-generated diet recommendations to condition-specific microbiome formulations; ready-to-consume nutraceutical powders designed for a targeted clinical outcome.

Powered by digital twin technology and advanced optimisation algorithms, the Enbiosis platform enables targeted interventions across a wide range of chronic conditions. Each formulation is developed through simulated testing inside a virtual replica of the patient’s microbiome, before any real-world application.

Dotted illustration of a human figure with the gut highlighted, surrounded by microorganism and DNA motifs

Turning the microbiome into therapeutic factory

The digital twin platform

Unlike traditional approaches that simply add beneficial microbes to the gut, Enbiosis instructs the existing microbiome to manufacture the molecules that the body needs. The gut becomes a programmable bioreactor; producing or suppressing specific metabolites, precisely where they are needed.

Breadth of application

The Enbiosis engine can now target more than 100 microbiome-related conditions; including diabetes, psoriasis, dry eye disease, inflammatory bowel disease and Alzheimer’s; and extends beyond health condition management into enhancing energy, sleep quality, mood and cognitive performance.

Clinical Results: Validated Success, Promising Signals

Dry eye

In the en-TEAR pilot (single-arm, open-label, n=20), tear production at 16 weeks rose 67% from baseline (Schirmer test, 10.0 to 16.7 mm), eight weeks after intake had stopped. The article has been submitted for peer review and reports every secondary endpoint, including those that did not reach significance.

tear production at week 16, eight weeks after intake had stopped
+67%
Schirmer test, baseline to week 16
10.0 to 16.7 mm

Prospective, single-arm, open-label pilot · 8-week intervention & 8-week post-intervention follow-up · n=20

Blood Glucose Control

Our latest pilot showed a promising early signal: en-JOY&FIT was associated with a meaningful shift in blood glucose control over twelve weeks, with both fasting glucose and HbA1c moving in a healthier direction. The same formulation is now being tested in two ongoing randomized, placebo-controlled trials, one in blood glucose regulation and one in weight management, to establish causality and durability.

Baseline

Fasting glucose · mean

142.0mg/dL

HbA1c · mean

7.6%

After 12 weeks

Fasting glucose · mean

117.8mg/dL

−24.2 mg/dL · p<0.001 · average reduction

HbA1c · mean

6.9%

−0.75 points · p<0.001

HbA1c: −0.91 points excluding 1 discordant case.
Fasting glucose improved in 21 of 25 participants with paired labs.
84%
HbA1c improved in 22 of 25. The single case that worsened rose discordantly even as its fasting glucose fell.
88%

Single-arm, open-label pilot · 12-week intervention · n=25

Recognition & Achievements

Enbiosis has been recognised by some of the most respected institutions and programmes in European deep tech and life sciences:

  • Tech Rocketship Awards

    UK Tech Rocketship Awards

    Gold Medal · 2022

    Awarded by the UK government (Department for Business and Trade) as one of the most promising technology companies from outside the UK; a flagship programme that effectively opened our UK market entry.

  • Sanofi

    Sanofi

    Country Winner · 2022

  • Probiota Americas

    Probiota Americas

    Scientific Frontiers Winner · 2023

  • NutraIngredients Awards

    NutraIngredients Awards

    Finalist · 2023

    Finalist for Product of the Year: Microbiome Modulation. The leading European award in the nutraceutical and functional-food industry.

  • UK Department for International Trade

    UK Department for International Trade recognition

    Enbiosis was named one of the best technology companies across Europe (including Israel) at time of assessment.

  • Digestive Disease Week 2023

    Digestive Disease Week & IFM International Conference

    Invited presentations of the multicentre IBS study, 2023.

Together, these milestones position Enbiosis not as a promising start-up, but as a mature, clinically-validated and globally recognised leader in AI-driven microbiome science.

Product family labelled Powered by Enbiosis: a bottle, jars, a sachet and a tube

Where we go from here

Enbiosis was founded on a simple, ambitious thesis: that food, when engineered with the precision of software, can do the work of medicine. With Enbioma, we proved the thesis clinically. With Enbiosis, we turn it into a product category.

We are now partnering with global health brands; in supplements, functional foods and beverages, and medical nutrition; to bring Enbiosis-designed formulations to consumers worldwide.